ObjectiveTo investigate the effect of moxifloxacin on serum paraoxonase 1 (PON1) activity, procalcitonin (PCT) levels and life quality on patients with drug-resistant pulmonary tuberculosis. MethodsA total of 78 patients with drug-resistant tuberculosis admitted to our hospital from January 2018 to December 2018 were enrolled and randomly divided into two groups. The control group (39 cases) received conventional chemotherapy and the observation group (39 cases) received moxifloxacin on the basis of conventional chemotherapy. PON1 activity, PCT levels and life quality were compared between the two groups. ResultsAfter 18 months of treatment, the observation group had significantly higher PON1 activity and life quality score as well as lower serum PCT level in comparison with the control group, and the difference was statistically significant (P＜0.05). ConclusionMoxifloxacin treatment can improve the PON1 activity on patients with drug-resistant tuberculosis, reduce serum PCT levels and improve their life quality.

无